Ulster University Logo

Ulster Institutional Repository

Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1

Biomedical Sciences Research Institute Computer Science Research Institute Environmental Sciences Research Institute Nanotechnology & Advanced Materials Research Institute

Kerr, Barry D., Flatt, Peter and Gault, Victor (2010) Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1. BIOCHEMICAL PHARMACOLOGY, 80 (3). pp. 396-401. [Journal article]

Full text not available from this repository.

DOI: 10.1016/j.bcp.2010.04.021

Abstract

Liraglutide, a GLP-1 mimetic has recently been approved for clinical use in obesity-diabetes. The purpose of this study was to assess if acylation of Liraglutide via its gamma-glutamyl linker contributes to DPP-IV inhibition and efficacy of the molecule, given that such an approach could be useful in prolonging bioactivity of related peptides. Liraglutide lacking the gamma-glutamyl linker (Lira-gamma Glu) and Liraglutide exhibited enhanced DPP-IV resistance with extension of t(1/2) plus effective cAMP production (EC50: 0.15 +/- 0.11 and 0.16 +/- 0.11 nM, respectively) compared to GLP-1 (EC50 3.81 +/- 0.80 nM). GLP-1, Lira-gamma Glu and Liraglutide increased insulin secretion compared to glucose (1.5-3.0-fold; p < 0.05 to p < 0.001). In vivo, Lira-gamma Glu and Liraglutide significantly lowered plasma glucose when administered 4 and 8 h prior to a glucose load (1.3-1.9-fold; p <0.05 top < 0.001). Twice-daily administration of Lira-gamma Glu and Liraglutide for 14 days significantly decreased food intake (1.2-fold; p < 0.05) and plasma glucose (1.1-1.6-fold; p < 0.05 to p < 0.01) whilst increasing plasma insulin (1.4-1.6-fold; p <0.05). At 14 days, Lira-gamma Glu and Liraglutide markedly improved glucose tolerance (1.4-3.4-fold; p < 0.05 to p < 0.001), insulin response to glucose (1.41.5-fold; p <0.05), insulin sensitivity (1.3-1.4-fold; p <0.05 to p <0.01), as well as increasing pancreatic insulin content (1.4-fold; p <0.05). Functional characteristics of Lira-gamma Glu and Liraglutide are almost indistinguishable, questioning necessity of gamma-glutamyl linker in acylation for generation of long-acting incretin mimetics. (C) 2010 Elsevier Inc. All rights reserved.

Item Type:Journal article
Faculties and Schools:Faculty of Life and Health Sciences
Faculty of Life and Health Sciences > School of Biomedical Sciences
Research Institutes and Groups:Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Diabetes
ID Code:14811
Deposited By:Dr Nigel Irwin
Deposited On:21 Sep 2010 15:17
Last Modified:21 Sep 2010 15:17

Repository Staff Only: item control page